

# IBS-C Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/IA2BB455199MEN.html>

Date: May 2018

Pages: 156

Price: US\$ 3,480.00 (Single User License)

ID: IA2BB455199MEN

## Abstracts

### Report Summary

IBS-C Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on IBS-C Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of IBS-C Drugs 2013-2017, and development forecast 2018-2023

Main market players of IBS-C Drugs in EMEA, with company and product introduction, position in the IBS-C Drugs market

Market status and development trend of IBS-C Drugs by types and applications

Cost and profit status of IBS-C Drugs, and marketing status

Market growth drivers and challenges

The report segments the EMEA IBS-C Drugs market as:

EMEA IBS-C Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA IBS-C Drugs Market: Product Type Segment Analysis (Consumption Volume,

Average Price, Revenue, Market Share and Trend 2013-2023):

Linaclotide  
Lubiprostone  
Osmotic Laxatives  
Stimulant Laxatives  
Other

EMEA IBS-C Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Pharmacies  
Retail Pharmacies  
Online Pharmacies

EMEA IBS-C Drugs Market: Players Segment Analysis (Company and Product introduction, IBS-C Drugs Sales Volume, Revenue, Price and Gross Margin):

Catalent Pharmaceuticals Solutions  
Nestle  
Abbott Laboratories  
Synergy Pharmaceuticals  
Sucampo Pharmaceuticals  
Novartis Pharma Ag  
Astellas Pharmaceuticals  
Ardelyx, Inc  
Synthetic Biologics, Inc  
Teva Pharmaceutical Industries  
Bama-Geve, SLU  
Ferring BV  
Ironwood Pharmaceuticals, Inc  
Salix Pharmaceuticals Ltd  
Norgine B.V  
Prometheus Laboratories Inc  
Actavis Nordic A/S  
Albireo Pharma Inc  
Yuhan Corp  
Astrazeneca Plc  
The Menarini Group

Ono Pharmaceutical Co., Ltd

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF IBS-C DRUGS**

- 1.1 Definition of IBS-C Drugs in This Report
- 1.2 Commercial Types of IBS-C Drugs
  - 1.2.1 Linaclotide
  - 1.2.2 Lubiprostone
  - 1.2.3 Osmotic Laxatives
  - 1.2.4 Stimulant Laxatives
  - 1.2.5 Other
- 1.3 Downstream Application of IBS-C Drugs
  - 1.3.1 Hospital Pharmacies
  - 1.3.2 Retail Pharmacies
  - 1.3.3 Online Pharmacies
- 1.4 Development History of IBS-C Drugs
- 1.5 Market Status and Trend of IBS-C Drugs 2013-2023
  - 1.5.1 Asia Pacific IBS-C Drugs Market Status and Trend 2013-2023
  - 1.5.2 Regional IBS-C Drugs Market Status and Trend 2013-2023

### **CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of IBS-C Drugs in Asia Pacific 2013-2017
- 2.2 Consumption Market of IBS-C Drugs in Asia Pacific by Regions
  - 2.2.1 Consumption Volume of IBS-C Drugs in Asia Pacific by Regions
  - 2.2.2 Revenue of IBS-C Drugs in Asia Pacific by Regions
- 2.3 Market Analysis of IBS-C Drugs in Asia Pacific by Regions
  - 2.3.1 Market Analysis of IBS-C Drugs in China 2013-2017
  - 2.3.2 Market Analysis of IBS-C Drugs in Japan 2013-2017
  - 2.3.3 Market Analysis of IBS-C Drugs in Korea 2013-2017
  - 2.3.4 Market Analysis of IBS-C Drugs in India 2013-2017
  - 2.3.5 Market Analysis of IBS-C Drugs in Southeast Asia 2013-2017
  - 2.3.6 Market Analysis of IBS-C Drugs in Australia 2013-2017
- 2.4 Market Development Forecast of IBS-C Drugs in Asia Pacific 2018-2023
  - 2.4.1 Market Development Forecast of IBS-C Drugs in Asia Pacific 2018-2023
  - 2.4.2 Market Development Forecast of IBS-C Drugs by Regions 2018-2023

### **CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole Asia Pacific Market Status by Types
  - 3.1.1 Consumption Volume of IBS-C Drugs in Asia Pacific by Types
  - 3.1.2 Revenue of IBS-C Drugs in Asia Pacific by Types
- 3.2 Asia Pacific Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in China
  - 3.2.2 Market Status by Types in Japan
  - 3.2.3 Market Status by Types in Korea
  - 3.2.4 Market Status by Types in India
  - 3.2.5 Market Status by Types in Southeast Asia
  - 3.2.6 Market Status by Types in Australia
- 3.3 Market Forecast of IBS-C Drugs in Asia Pacific by Types

## **CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of IBS-C Drugs in Asia Pacific by Downstream Industry
- 4.2 Demand Volume of IBS-C Drugs by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of IBS-C Drugs by Downstream Industry in China
  - 4.2.2 Demand Volume of IBS-C Drugs by Downstream Industry in Japan
  - 4.2.3 Demand Volume of IBS-C Drugs by Downstream Industry in Korea
  - 4.2.4 Demand Volume of IBS-C Drugs by Downstream Industry in India
  - 4.2.5 Demand Volume of IBS-C Drugs by Downstream Industry in Southeast Asia
  - 4.2.6 Demand Volume of IBS-C Drugs by Downstream Industry in Australia
- 4.3 Market Forecast of IBS-C Drugs in Asia Pacific by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IBS-C DRUGS**

- 5.1 Asia Pacific Economy Situation and Trend Overview
- 5.2 IBS-C Drugs Downstream Industry Situation and Trend Overview

## **CHAPTER 6 IBS-C DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC**

- 6.1 Sales Volume of IBS-C Drugs in Asia Pacific by Major Players
- 6.2 Revenue of IBS-C Drugs in Asia Pacific by Major Players
- 6.3 Basic Information of IBS-C Drugs by Major Players
  - 6.3.1 Headquarters Location and Established Time of IBS-C Drugs Major Players
  - 6.3.2 Employees and Revenue Level of IBS-C Drugs Major Players
- 6.4 Market Competition News and Trend

- 6.4.1 Merger, Consolidation or Acquisition News
- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

## **CHAPTER 7 IBS-C DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

### 7.1 Catalent Pharmaceuticals Solutions

- 7.1.1 Company profile
- 7.1.2 Representative IBS-C Drugs Product
- 7.1.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Catalent Pharmaceuticals Solutions

### 7.2 Nestle

- 7.2.1 Company profile
- 7.2.2 Representative IBS-C Drugs Product
- 7.2.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Nestle

### 7.3 Abbott Laboratories

- 7.3.1 Company profile
- 7.3.2 Representative IBS-C Drugs Product
- 7.3.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories

### 7.4 Synergy Pharmaceuticals

- 7.4.1 Company profile
- 7.4.2 Representative IBS-C Drugs Product
- 7.4.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synergy Pharmaceuticals

### 7.5 Sucampo Pharmaceuticals

- 7.5.1 Company profile
- 7.5.2 Representative IBS-C Drugs Product
- 7.5.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Sucampo Pharmaceuticals

### 7.6 Novartis Pharma Ag

- 7.6.1 Company profile
- 7.6.2 Representative IBS-C Drugs Product
- 7.6.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Novartis Pharma Ag

### 7.7 Astellas Pharmaceuticals

- 7.7.1 Company profile
- 7.7.2 Representative IBS-C Drugs Product
- 7.7.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharmaceuticals

### 7.8 AstraZeneca

- 7.8.1 Company profile
- 7.8.2 Representative IBS-C Drugs Product
- 7.8.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca

## 7.8 Ardelyx, Inc

### 7.8.1 Company profile

### 7.8.2 Representative IBS-C Drugs Product

### 7.8.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ardelyx, Inc

## 7.9 Synthetic Biologics, Inc

### 7.9.1 Company profile

### 7.9.2 Representative IBS-C Drugs Product

### 7.9.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synthetic Biologics, Inc

## 7.10 Teva Pharmaceutical Industries

### 7.10.1 Company profile

### 7.10.2 Representative IBS-C Drugs Product

### 7.10.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries

## 7.11 Bama-Geve, SLU

### 7.11.1 Company profile

### 7.11.2 Representative IBS-C Drugs Product

### 7.11.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Bama-Geve, SLU

## 7.12 Ferring BV

### 7.12.1 Company profile

### 7.12.2 Representative IBS-C Drugs Product

### 7.12.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ferring BV

## 7.13 Ironwood Pharmaceuticals, Inc

### 7.13.1 Company profile

### 7.13.2 Representative IBS-C Drugs Product

### 7.13.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ironwood

## Pharmaceuticals, Inc

## 7.14 Salix Pharmaceuticals Ltd

### 7.14.1 Company profile

### 7.14.2 Representative IBS-C Drugs Product

### 7.14.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals

## Ltd

## 7.15 Norgine B.V

### 7.15.1 Company profile

### 7.15.2 Representative IBS-C Drugs Product

### 7.15.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Norgine B.V

## 7.16 Prometheus Laboratories Inc

## 7.17 Actavis Nordic A/S

## 7.18 Albireo Pharma Inc

## 7.19 Yuhan Corp

- 7.20 AstraZeneca Plc
- 7.21 The Menarini Group
- 7.22 Ono Pharmaceutical Co., Ltd

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IBS-C DRUGS**

- 8.1 Industry Chain of IBS-C Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IBS-C DRUGS**

- 9.1 Cost Structure Analysis of IBS-C Drugs
- 9.2 Raw Materials Cost Analysis of IBS-C Drugs
- 9.3 Labor Cost Analysis of IBS-C Drugs
- 9.4 Manufacturing Expenses Analysis of IBS-C Drugs

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF IBS-C DRUGS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source



- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: IBS-C Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/IA2BB455199MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IA2BB455199MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970